Scott Armstrong, DO
Family Medicine · Auburn, INNPI 1861402760
Payments from drug & device makers
Across 259 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$815
- AstraZeneca$594
- Novo Nordisk$392
- GSK$244
- Biohaven Pharmaceutical Holding Company Ltd.$239
- Pfizer$196
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,281100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 72 | $815 |
| AstraZeneca | 28 | $594 |
| Novo Nordisk | 22 | $392 |
| GSK | 14 | $244 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $239 |
| Pfizer | 11 | $196 |
| Lilly USA, LLC | 13 | $189 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $155 |
| Axsome Therapeutics, Inc. | 3 | $136 |
| Supernus Pharmaceuticals, Inc. | 7 | $134 |
| Exact Sciences | 8 | $123 |
| Boehringer Ingelheim | 7 | $112 |
| Amgen | 7 | $108 |
| Abbott | 4 | $79 |
| Lundbeck LLC | 5 | $77 |
| Sanofi-aventis U.S. LLC | 5 | $76 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $71 |
| Amarin Pharma, Inc. | 3 | $53 |
| Antares Pharma, Inc. | 3 | $47 |
| Bausch Health US, LLC | 3 | $45 |
| Halozyme Inc | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Johnson & Johnson | 3 | $37 |
| Novartis | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 1 | $28 |
| Genentech USA, Inc. | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Exeltis, USA Inc. | 1 | $19 |
| Resmed Corp | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$125
- FARXIGA$125
- AREXVY$121
How this compares
$4,297 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 101 | $133,917 |
| JardianceEmpagliflozin | 59 | $73,831 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $69,503 |
| FarxigaDapagliflozin Propanediol | 67 | $68,322 |
| TrulicityDulaglutide | 37 | $48,596 |
| EliquisApixaban | 45 | $45,696 |
| RybelsusSemaglutide | 22 | $35,595 |
| JanuviaSitagliptin Phosphate | 27 | $34,433 |
| XareltoRivaroxaban | 20 | $31,037 |
| MounjaroTirzepatide | 16 | $30,138 |
| LinzessLinaclotide | 33 | $28,197 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $26,152 |
| QuliptaAtogepant | 15 | $23,479 |
| TrintellixVortioxetine Hydrobromide | 13 | $18,419 |
| Spiriva RespimatTiotropium Bromide | 16 | $12,013 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $392 | $169,512123 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $244 | $95,65697 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $112 | $85,84475 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $189 | $78,73453 claims |
| AstraZenecaFarxiga | $594 | $68,32267 claims |
| AbbVieLinzess, Qulipta | $815 | $51,67648 claims |
| PfizerEliquis | $196 | $45,69645 claims |
| Johnson & JohnsonXarelto | $37 | $31,03720 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $155 | $18,41913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Auburn
- Mark SouderAuburn$24K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.